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Oxidative stress has been suggested to play a role in hypertension and hypertension induced organ damage. This study examined
the effect of enalapril, an antihypertensive drug, on oxidative stress markers and antioxidant enzymes in kidney of spontaneously
hypertensive rat (SHR) and N𝜔 -nitro-L-arginine methyl ester (L-NAME) administered SHR. Male rats were divided into four
groups (SHR, SHR+enalapril, SHR+L-NAME, and SHR+enalapril+L-NAME). Enalapril (30mg kg−1 day−1) was administered from
week 4 to week 28 and L-NAME (25mg kg−1 day−1) was administered from week 16 to week 28 in drinking water. Systolic blood
pressure (SBP) wasmeasured during the experimental period. At the end of experimental periods, rats were sacrificed; urine, blood,
and kidneys were collected for the assessment of creatinine clearance, total protein, total antioxidant status (TAS), thiobarbituric
acid reactive substances (TBARS), superoxide dismutase (SOD), and catalase (CAT), as well as histopathological examination.
Enalapril treatment significantly enhanced the renal TAS level (𝑃 < 0.001) and SOD activity (𝑃 < 0.001), reduced the TBARS
levels (𝑃 < 0.001), and also prevented the renal dysfunction and histopathological changes. The results indicate that, besides its
hypotensive and renoprotective effects, enalapril treatment also diminishes oxidative stress in the kidneys of both the SHR and
SHR+L-NAME groups.
1. Introduction
Hypertension is a global chronic health condition in which
systemic arterial pressure is persistently elevated. It is of great
public concern as prolonged, uncontrolled hypertension
leads to cardiovascular diseases and organ damage including
the kidneys, resulting in nephropathy, chronic renal disease,
and ultimately renal failure [1]. This makes it the leading
behavioural and physiological risk factor for attributable
deaths, accounting for 13% of global deaths [2].
The pathogenesis of essential hypertension is multifacto-
rial and highly complex as various factorsmodulate the blood
pressure in the body [3]. In this respect, free radical medi-
ated oxidative damage has been proposed as an important
predisposing pathogenic mechanism in the development and
progression of hypertension and its complications including
organ damage [4, 5]. Free radicals and their metabolites,
reactive oxygen species (ROS), are constantly formed in the
body by several mechanisms. These substances, being reac-
tive, can cause oxidative damage to biological molecules. The
body possesses antioxidant systems that are very important to
protect cellular components from free radical induced oxida-
tive damage. These consist of nonenzymatic and enzymatic
systems including SOD and CAT [6]. Under physiological
conditions, ROS produced in the course of metabolism are
contained by the body’s antioxidant defence mechanism.
When these defence mechanisms are inadequate, either due
to increased ROS production or diminished antioxidant
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levels, oxidative stress occurs [7]. Oxidative stress which leads
to damage of biological molecules, such as lipids, proteins,
carbohydrates, and DNA, can inflict tissue injury and dys-
function [8]. Several reports have documented that hyperten-
sion is associated with increased free radical production as
well as reduction of antioxidant capacity [9, 10]. High levels
of lipid peroxidation biomarkers [11, 12] as well as hydrogen
peroxide [13] in patients with essential hypertension suggest
the probable involvement of free radicals in this disease and
its long term complications.
As hypertension contributes to organ damage, antihyper-
tensive drug treatment aims to reduce blood pressure and
hypertension induced organ damage including the kidneys.
In this respect, studies have shown that certain antihy-
pertensive drugs, in particular those that target the renin-
angiotensin system, are able to blunt the progression of renal
disease in hypertension [14–17]. Some studies have suggested
that the therapeutic benefit of antihypertensive drugs includ-
ing renoprotection could be in part due to their antioxidant
properties whereby there is inhibition of free radical pro-
duction. These studies involving both human and animal
models, including the SHR, have demonstrated that certain
groups of antihypertensive drugs, such as the angiotensin
converting enzyme inhibitors (ACEi), angiotensin receptor
blockers (ARB), and calcium channel blockers (CCB), lower
blood pressure and cause changes in the oxidative status [18–
22].
Even though antihypertensive drug treatments have been
shown to reduce blood pressure and certain oxidative stress
parameters, the studies concerned were not comprehensive
as no in-depth study on the effect of these antihypertensive
drug treatments on the antioxidant mechanisms involved as
kidney damage progresses has been carried out. As such, the
biochemical mechanisms by which these antihypertensive
drugsmight inhibit oxidative stress, especially in the kidneys,
are not well known. Further studies are needed to clarify
whether these antihypertensive drugs function by affecting
the antioxidant defence mechanisms in the kidneys or just
primarily correct the altered mechanical forces that cause
structural changes in the kidney.
The SHR is a suitable model for the study of essential
hypertension as the natural progression of hypertension and
organ damage including the kidneys is remarkably similar to
man. As in humans, kidney damage and progressive decline
in glomerular filtration rate (GFR) occur at a much later
stage in the SHR. Time-course studies until this stage of
renal damage require maintaining SHR until an advanced
age which would take a very long time and is costly. This is
overcome by the usage of the L-NAME administered SHR
model which produces renal damage similar to those seen in
human hypertensive nephropathy [23]. This model has been
used for studies on hypertensive nephropathy [24–26].
Overall the effect of ACEi in lowering blood pressure
on oxidative stress parameters and related protective mech-
anisms in the kidney has not been well studied neither in
humans nor in SHR. As such, this study was undertaken
to see the effect of enalapril, a widely used ACEi class
antihypertensive drug, on the control of hypertension and the
role of oxidative stress and antioxidant defence mechanisms
in hypertension, as the subsequent renal damage progresses
in SHR and L-NAME administered SHR.
2. Methods
2.1. Animals. Male SHR and Wistar-Kyoto (WKY) rats aged
just below 4 weeks, obtained from the Animal Research and
Service Centre (ARASC), Health Campus, Universiti Sains
Malaysia, Kelantan, Malaysia, were used for the study.
2.2. Experimental Protocols. Theexperimental protocols used
in this study were approved by the Animal Ethics andWelfare
Committee of Universiti Sains Malaysia, Kelantan, Malaysia.
SHR were divided into 4 different groups of six rats each:
(1) SHR (untreated): SHR,
(2) SHR treated with enalapril (age: 4 weeks–28 weeks):
SHR+E,
(3) SHR administered L-NAME (age: 16 weeks–28
weeks): SHR+LN,
(4) SHR treated with enalapril (age: 4 weeks–28 weeks)
and L-NAME (age: 16 weeks–28 weeks): SHR+E+LN.
Control normotensiveWKY ratswere similarly divided into 4
groups (𝑛 = 6/group) and treated in the samemanner as SHR
groups. Each rat was housed in individual cage in standard
controlled environment: room temperature of 25–27∘Cunder
12-hour-light and 12-hour-dark cycle (lights on 0700–1900
hours). The animals were fed with standard commercial rat
food and water ad libitum.
2.3. Enalapril and L-NAME Administration. After acclimati-
zation of the rats in the cages, the average daily water intake
of rats was determined. Both enalapril (Ranbaxy, Malaysia)
and L-NAME (Sigma Chemicals, USA) were given to rats
through their daily drinking water in the following doses:
enalapril 30mg kg−1 day−1, L-NAME 25mg kg−1 day−1. Both
dosage formulations were prepared freshly each day by
dissolving the compounds in slightly less volume of daily
water consumption to ensure their complete dosage intake.
The daily water consumption was monitored to ensure the
dosage was adhered to. Extra drinking water was provided
after the required dosage had been taken. Concentration of
both compounds in water was adjusted accordingly to match
the age-related increase in body weight of the rats.
2.4. Physical Parameter Measurements. Body weight of rats
was measured every week using a top pan balance by placing
the rat in a small weighed cage. SBP was measured every
two weeks in conscious rats during the experimental period
by the noninvasive (indirect) blood pressure (NIBP) tail
plethysmography method, using an automated cuff inflator-
pulse detection system (Model 6R22931, IITC Life Science,
USA). An average of three readings was taken for each
measurement.
2.5. Specimen Collection and Processing. One to two days
before 4 weeks, 16 weeks, and 28 weeks of age, the rats
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were placed in metabolic cages for collection of 24-hour
urine. Collected urine was stored at −80∘C until analysis.
Rats were weighed and sacrificed at the end of 28 weeks.
Blood samples were collected in plain tubes, allowed to
clot, centrifuged to obtain serum, and then stored at −80∘C
until analysis. Kidneys were rapidly removed, washed in
saline, decapsulated, blot-dried, and weighed. One kidney
was cut transversely and one half was used for histopathology
examination. Other kidney tissues were used for kidney
homogenate preparation.
2.6. Histopathology Examination. Routine histopathology
procedures were followed whereby kidney sections were
fixed with 10% neutral buffered formaldehyde for 2 days,
dehydrated, and then embedded in paraffin. Paraffin sections
were made at 3 𝜇m and stained with haematoxylin/eosin
(HE) for microscopic study to assess any glomerular, tubular,
and vascular changes.
2.7. Preparation of Kidney Homogenates. A weighed amount
of kidney tissue was homogenized to make 10% homogenates
(w/v) in ice cold (0–4∘C) 0.05M sodium phosphate buffer
pH 7.4, using an ice-chilled glass homogenizing vessel in a
homogenizer fitted with Teflon pestle (Glass-Col, USA) at
900 rpm.The homogenates were centrifuged in a refrigerated
centrifuge at 1,000×g at 4∘C for 10 minutes to remove nuclei
and debris [27]. The supernatant obtained was used for
biochemical assays. TBARS assay was carried out on the day
of sacrifice. Homogenates were kept frozen at −80∘C until
analysis for the other assays.
2.8. Biochemical Assays
2.8.1. Total Protein. Protein concentration of urine and kid-
ney homogenates was determined using the Micro TP kit
(Wako Pure Chemicals, Japan) according to the method of
Watanabe et al. [28].This method is a pyrogallol dye-binding
spectrophotometric assay with bovine serum albumin (BSA)
as the standard. To 1mL of the Micro TP reagent 0.01mL
of sample or BSA standard was added and mixed. The
reaction mixtures were left at room temperature for 15
minutes before absorbance was read at wavelength of 600 nm
using a spectrophotometer (Ultrospec 1100 Pro, UK). Protein
concentration in mg/day (for urine) and mg/L (for kidney
homogenates) was calculated using the BSA standard.
2.8.2. Creatinine. Serum and urine creatinine were deter-
mined by the kinetic alkaline picrate method using a com-
mercial reagent kit (Randox Laboratories, Crumlin, UK).
Creatinine clearance was calculated from these data.
2.9. Oxidative Stress Markers
2.9.1. TAS. TAS was assessed according to the method of
Koracevic et al. [29]. It is based on the principle that
a standardized solution of Fe-EDTA complex reacts with
hydrogen peroxide by a Fenton-type reaction, leading to
the formation of hydroxyl radicals. These reactive oxygen
species degrade benzoate, resulting in the release of TBARS.
Antioxidants from the added sample of kidney homogenate
cause suppression of the production of TBARS that was pro-
portional to their concentration. This reaction is measured
spectrophotometrically at 532 nmand the inhibition of colour
development is defined as the TAS. The assay was performed
as follows.
10 𝜇L of kidney homogenate was pipetted in a test tube
containing 0.49mL of 100mM sodiumphosphate buffer.This
was followed by the addition of 0.5mL of 10mM sodium
benzoate solution, 0.2mL of Fe-EDTA mixture, and 0.2mL
of 10mM H
2
O
2
solution. Negative control (with phosphate
buffer instead of the kidney homogenate) containing similar
reagents as in sample test tubes was also prepared. The test
tubes were vortexed and incubated at 37∘C for 60 minutes.
This was followed by the addition of 1mL of 20% acetic acid
and 0.8% (w/v) thiobarbituric acid (TBA).The reaction tubes
were incubated at 100∘C for 10minutes. After cooling to room
temperature, the absorbance of the mixture was measured
spectrophotometrically at 532 nm against distilled water. TAS
in the kidney homogenates was calculated using uric acid as
standard. TAS was expressed as 𝜇mol uric acid equivalent per
mg protein.
2.9.2. TBARS. Lipid peroxidation was determined as TBARS
according to the method of Chatterjee et al. [30]. MDA, an
end product of fatty acid peroxidation, reacts with TBA to
form a coloured complex which has maximum absorbance at
532 nm. 1,1,3,3-Tetraethoxypropane (TEP), a form of MDA,
was used as standard in this assay. Briefly, 1.5mL of 20%
glacial acetic acid (pH 3.5), 0.2mL of 8.1% sodium dodecyl
sulphate (SDS), 1.5mL of 0.8% (w/v) thiobarbituric acid
(TBA), 0.7mL of distilled water, and 0.1mL of kidney
homogenate or MDA standard were pipetted into test tubes.
The test tubes were vortexed (Stuart, UK) and then kept
in a boiling water bath (Memmert, Germany) at 95∘C for
60 minutes with a marble on top of each test tube. After
cooling, the test tubes were centrifuged at 3000×g for 10
minutes. One mL of each supernatant was transferred to
cuvette and absorbance was read at 532 nm on a spectropho-
tometer (Ultrospec 1100 Pro, UK). The concentration of each
sample was determined from a standard curve based on its
absorbance. TBARS levels were represented as 𝜇mol MDA
equivalent per mg protein.
2.10. Antioxidant Enzymes
2.10.1. SOD. SOD activity was assayed according to the
method of Dogan et al. [31]. The oxidation of epinephrine is
followed in terms of the production of adrenochrome which
exhibits an absorption maximum at 480 nm. SOD removes
O.−
2
from reaction mixtures by catalyzing its dismutation to
O
2
andH
2
O
2
thereby inhibiting autoxidation of epinephrine.
Measurement of autoxidation of epinephrine was determined
by pipetting 2mL of 0.08M sodium bicarbonate buffer
solution (pH 10.2) into a cuvette, followed by 0.5mL of
0.75mM ethylenediaminetetraacetic acid (EDTA) solution.
The reaction was started by adding 0.5mL of 4.37mM
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epinephrine into the cuvette and changes in absorbance were
measured at wavelength of 480 nm at 30-second intervals for
6 minutes after adding epinephrine. Measurement of SOD
in kidney homogenate was performed by pipetting 1.95mL
of 0.08M sodium bicarbonate buffer solution (pH 10.2),
0.5mL of 0.75mM EDTA solution, and 0.05mL of kidney
homogenate into a cuvette. Changes in absorbance were read
at wavelength 480 nm every 30 seconds over a period of 6
minutes after adding 0.5mL of 4.37mM epinephrine solu-
tion, using a spectrophotometer. SOD activity was expressed
as unit per mg protein. One unit (U) of SOD was defined as
the amount of enzyme that inhibits the rate of autoxidation
of epinephrine by 50%.
2.10.2. CAT. CAT activity was assayed according to the
method of Goth [32]. The method is based on the enzyme-
catalyzed decomposition of hydrogen peroxide and assay
of the remaining hydrogen peroxide. Hydrogen peroxide
and molybdate ions formed a yellowish complex which
has maximum absorbance at 405 nm. The assay requires 4
reaction tubes: Blank 1, Blank 2, Blank 3, and the sample. For
Blank 1, Blank 2, and Blank 3, the reagents were added in
sequence. Blank 1 contains 0.5mL substrate (65mM hydro-
gen peroxide in 60mM sodium-potassium phosphate buffer,
pH 7.4), 0.5mL 32.4mM ammonium molybdate solution,
and 0.1mL kidney homogenate; Blank 2 contains 0.5mL
substrate, 0.5mL ammoniummolybdate solution, and 0.1mL
sodium-potassiumphosphate buffer; Blank 3 contains 0.6mL
sodium-potassium phosphate buffer and 0.5mL ammonium
molybdate. For sample tubes, 0.1mL kidney homogenate was
incubated in 0.5mL substrate at 37∘C for 60 seconds. The
enzymatic reaction was stopped with 0.5mL ammonium
molybdate solution and the yellow complex ofmolybdate and
hydrogen peroxide was measured at wavelength of 405 nm
against Blank 3. CAT activity was expressed as unit per
mg protein. One unit of CAT was defined as the amount
of enzyme that catalyzes the decomposition of 1 𝜇mol of
hydrogen peroxide per minute.
2.11. Statistical Analysis. Data were analyzed by one-way
ANOVAwith post hoc Tukey test using Statistical Package for
the Social Science (SPSS) software version 20. Significant level
was set (𝑃 < 0.05). Data are expressed as mean and standard
error mean (mean ± SEM) for six animals in each group.
3. Results
3.1. Kidney Weight and Kidney to Body Weight Ratio. There
was no significant difference in the absolute kidney weight
of SHR and SHR+E at 16 weeks. However at 28 weeks the
absolute kidney weight of SHR, SHR+LN, and SHR+E+LN
was significantly increased (𝑃 < 0.01, a∗∗) when compared
to SHR+E. There was no significant difference in absolute
kidney weight among SHR, SHR+LN, and SHR+E+LN at 28
weeks (Figure 1). The kidney to body weight ratio for SHR+E
was significantly reduced at both 16 weeks and 28 weeks
when compared to SHR, SHR+LN, and SHR+E+LN (𝑃 <
0.01, b∗∗). Kidney to body weight ratio was also significantly
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Figure 1: Kidney weight of enalapril treated and untreated SHR and
SHRadministered L-NAME. a∗∗𝑃 < 0.01 SHR+E compared to SHR,
SHR+LN, and SHR+E+LN.
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Figure 2: Kidney to body weight ratio of enalapril treated and
untreated SHR and SHR administered L-NAME. a∗∗𝑃 < 0.01
SHR+E compared to SHR (16 weeks), b∗∗𝑃 < 0.01 SHR+E
compared to SHR (28 weeks), and c∗∗𝑃 < 0.01 SHR+E+LN
compared to SHR+LN.
reduced in SHR+E+LN at 28 weeks when compared to
untreated SHR+LN (𝑃 < 0.01, c∗∗) (Figure 2).
3.2. SBP. The SBP of enalapril treated and untreated SHR
and SHR+LN are presented in Figure 3. SBP of SHR treated
with enalapril (SHR+E) were significantly lower from the
age of 8 weeks until that of 28 weeks when compared to
untreated SHR (𝑃 < 0.001, a∗∗∗). L-NAMEwas administered
to rats at the age of 16 weeks onwards. After administration
of L-NAME, SHR+LN showed significant increase in SBP
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Figure 3: SBP of enalapril treated and untreated SHR and SHR
administered L-NAME. a∗∗∗𝑃 < 0.001 SHR compared to SHR+E,
b∗∗𝑃 < 0.01, b∗∗∗𝑃 < 0.001 SHR+LN compared to SHR, c∗∗∗𝑃 <
0.001 SHR+E+LN compared to SHR+LN, d∗𝑃 < 0.05, d∗∗𝑃 <
0.01, and d∗∗∗𝑃 < 0.001 SHR+E+LN compared to SHR+E. (Note
that from week 4 to week 16 the data for the groups SHR+LN and
SHR+E+LN are approximately similar to that of SHR and SHR+E
rats, respectively, that have not been treated with L-NAME yet.)
from week 22 until week 28 compared to SHR (𝑃 < 0.01
b∗∗; 𝑃 < 0.001, b∗∗∗). The SHR+LN group treated with
enalapril (SHR+E+LN) showed significant decrease com-
pared to untreated SHR+LN (𝑃 < 0.001, c∗∗∗) from week
18 until week 28. However the SBP levels of this SHR+E+LN
group were still above normal at weeks 22, 24, 26, and
28. When compared to the SHR+E group, the SBP of the
SHR+E+LN group showed significant increase from week 18
onwards until week 28 (𝑃 < 0.05, d∗, 𝑃 < 0.01, d∗∗, and
𝑃 < 0.001, d∗∗∗).
3.3.Histopathological Examination. Histopathological exam-
ination showed no pathological glomerular, tubular, or blood
vessel changes in SHR at 4 and 16 weeks. However at 28
weeks, SHR showed some presence of minimal blood vessel
medial hypertrophy. SHR+LN at 28 weeks showed significant
pathological changes in the glomerulus, tubules, and blood
vessels: glomerulosclerosis, shrunken or collapsed glomeruli,
increased mesangial cells, presence of inflammatory cells,
tubular atrophy and dilatation with casts, and blood vessel
hypertrophy. These pathological changes were prevented by
enalapril treatment (Figure 4).
3.4. Biochemical Parameters
3.4.1. Urinary Protein. Figure 5 shows the urinary protein
levels in enalapril treated and untreated SHR and SHR+LN.
Urinary protein was significantly increased in the untreated
SHR group at 28 weeks when compared to the SHR+E group
(𝑃 < 0.01, a∗∗). The greatly increased proteinuria in the
SHR+LN group was significantly reduced when treated with
enalapril (SHR+E+LN group: 𝑃 < 0.001, b∗∗∗).
3.4.2. Creatinine Clearance. Figure 6 shows the creatinine
clearance levels in enalapril treated and untreated SHR and
SHR+LN. Creatinine clearance was significantly reduced in
the untreated SHR+LN group when compared with the
SHR+E+LN group (𝑃 < 0.001, b∗∗∗).
3.4.3. TAS. Figure 7 represents the kidney TAS levels in
enalapril treated and untreated SHR and SHR+LN. There
was no significant difference in TAS levels between SHR and
SHR+E at 16 and 28 weeks. However the SHR+LN group
showed significantly reduced TAS levels at 28 weeks when
compared with the other groups (𝑃 < 0.001, a∗∗∗).
3.4.4. TBARS. The kidney TBARS levels of enalapril treated
and untreated SHR and SHR+LN are shown in Figure 8.
There was no significant difference in TBARS levels between
SHR and SHR+E at 16 weeks. However at 28 weeks, SHR
showed significant increase in TBARS when compared to
SHR+E (𝑃 < 0.001, a∗∗∗). SHR+LN had the highest
TBARS levels at 28 weeks, showing significant increase when
compared to all the other groups (𝑃 < 0.001, b∗∗∗). Results
also showed that enalapril treatment successfully prevented
the increase in TBARS levels in both SHR and SHR+LN rat
groups at 28 weeks.
3.4.5. SOD. There was no significant difference in kidney
SOD activity between SHR and SHR+E at 16 weeks. At
28 weeks, SHR showed significant decrease in SOD when
compared to SHR+E (𝑃 < 0.05, a∗). SHR+LN had the lowest
SOD levels at 28 weeks, showing significant decrease when
compared to all the other groups (𝑃 < 0.001, b∗∗∗). Results
also showed that enalapril treatment successfully enhanced
SOD levels in both SHR+E and SHR+E+LN rat groups at 28
weeks (Figure 9).
3.4.6. CAT. KidneyCAT activity (Figure 10) was significantly
increased in SHR at 16 weeks (𝑃 < 0.001, a∗∗∗) and 28 weeks
(𝑃 < 0.001, b∗∗∗) when compared to SHR+E group. CAT
activity was the lowest in the SHR+LN group at 28 weeks
and significantly reducedwhen compared to the other groups
(𝑃 < 0.001, c∗∗∗).
3.5. SBP, Biochemical, Oxidative Stress Parameters, and An-
tioxidant Enzyme Levels in Enalapril Treated and Untreated
WKY and WKY+L-NAME. WKY rats showed normal SBP
throughout the study period for the WKY and WKY+E
groups. L-NAME administration in WKY significantly
increased the SBP from 20 weeks onwards (𝑃 < 0.001)
when compared to untreated WKY. Enalapril treatment
significantly reduced the SBP in WKY+LN when compared
to untreated WKY+LN; however the level was still slightly
above normal (data not shown).
Table 1 shows the urinary protein, creatinine clearance,
and kidney oxidative stress parameters and antioxidant
enzymes SOD and CAT of treated and untreated normoten-
sive WKY and WKY+LN rats. At 28 weeks, WKY+LN had
significantly reduced TAS levels when compared to the other
groups (a∗∗∗𝑃 < 0.001). Similarly, SOD was significantly
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Figure 4: Kidney section HE stains of enalapril treated and untreated SHR and SHR administered L-NAME. (A) SHR at 16 weeks showing
no abnormal changes (40x); (B) SHR at 28 weeks showing presence of mild blood vessel changes, medial hypertrophy (100x); (C) SHR+E at
28 weeks showing no abnormal changes (40x); (D) SHR+LN at 28 weeks showing collapsed glomerulus (a), blood vessel hypertrophy (b),
and tubular casts (c)(40x); (E) SHR+LN at 28 weeks showing collapsed glomerulus (a), casts (b), and blood vessel hypertrophy (c) (100x); (F)
SHR+E+LN at 28 weeks showing no abnormal changes.
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Figure 6: Creatinine clearance levels in enalapril treated and
untreated SHR and SHR+LN. a∗∗𝑃 < 0.01 SHR compared to
SHR+E; b∗∗∗𝑃 < 0.001 SHR+LN compared to SHR+E+LN.
Oxidative Medicine and Cellular Longevity 7
Table 1: Effect of enalapril treatment on urinary protein, creatinine clearance, kidney TAS, TBARS, SOD, and CAT levels in treated and
untreated WKY and WKY administered L-NAME rats.
Parameters Groups
Age WKY WKY+E WKY+LN WKY+E+LN
TAS
(umol/mg protein)
4 weeks 2.52 ± 0.03 — — —
16 weeks 3.21 ± 0.06 3.34 ± 0.06 — —
28 weeks 3.47 ± 0.04 3.48 ± 0.05 2.67 ± 0.12a∗∗∗ 3.68 ± 0.06
TBARS
(umol/mg protein)
4 weeks 1.87 ± 0.05 — — —
16 weeks 1.96 ± 0.11 1.94 ± 0.16 — —
28 weeks 2.28 ± 0.11 2.23 ± 0.13 3.05 ± 0.12a∗∗∗ 2.15 ± 0.06
SOD
(U/mg protein)
4 weeks 82.50 ± 5.8 — — —
16 weeks 78.50 ± 3.94 82.33 ± 2.53 — —
28 weeks 79.50 ± 3.10 78.83 ± 2.20 61.33 ± 1.17a∗∗ 74.83 ± 0.95
CAT
(U/mg protein)
4 weeks 857 ± 21 — — —
16 weeks 781 ± 14 706 ± 7 — —
28 weeks 768 ± 12 698 ± 15 725 ± 22 699 ± 16
Urinary protein (mg/day)
4 weeks 0.98 ± 0.22 — — —
16 weeks 5.16 ± 0.41 6.08 ± 0.42 — —
28 weeks 5.28 ± 0.34 5.95 ± 0.43 9.19 ± 0.39a∗∗ 5.80 ± 0.30
Creatinine clearance
(mL/min)
4 weeks 0.59 ± 0.05 — — —
16 weeks 1.69± 0.06 1.67 ± 0.07 — —
28 weeks 1.79± 0.08 1.77 ± 0.08 1.47 ± 0.03a∗∗ 1.76 ± 0.07
Values are expressed as mean ± SEM (𝑛 = 6 per group).
WKY: WKY with no treatment, WKY+E :WKY+enalapril, WKY+LN :WKY+L-NAME, and WKY+E+LN :WKY+enalapril+L-NAME.
a∗∗
𝑃 < 0.01 and a∗∗∗𝑃 < 0.001WKY+LN compared to WKY, WKY+E, and WKY+E+LN.
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Figure 7: Kidney TAS levels in enalapril treated and untreated
SHR and SHR administered L-NAME. a∗∗∗𝑃 < 0.001 SHR+LN
compared to SHR, SHR+E, and SHR+E+LN.
reduced (a∗∗𝑃 < 0.01) and TBARS significantly increased
(a∗∗∗𝑃 < 0.001) in the WKY+LN group at 28 weeks when
compared to the other groups. No significant difference was
seen in CAT activity between the different groups at 16 and
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Figure 8: Kidney TBARS levels in enalapril treated and untreated
SHR and SHR administered L-NAME. a∗∗∗𝑃 < 0.001 SHR
compared to SHR+E, b∗∗∗𝑃 < 0.001 SHR+LN compared to SHR+E
and SHR+E+LN, and c∗∗𝑃 < 0.01 SHR+LN compared to SHR.
28 weeks. At 28 weeks, urinary protein was significantly
increased (a∗∗𝑃 < 0.01) and creatinine clearance significantly
decreased (a∗∗𝑃 < 0.01) in the WKY+LN group when
compared to the other groups.
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Figure 9: Kidney SOD activity in enalapril treated and untreated
SHR and SHR administered L-NAME. a∗𝑃 < 0.05 SHR compared
to SHR+E; b∗∗∗𝑃 < 0.001 SHR+LN compared to SHR, SHR+E, and
SHR+E+LN.
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Figure 10: Kidney CAT activity in enalapril treated and untreated
SHR and SHR administered L-NAME (16weeks: a∗∗∗𝑃 < 0.001 SHR
compared to SHR+E; 28 weeks: b∗∗∗𝑃 < 0.001 SHR compared to
SHR+E and c∗∗∗𝑃 < 0.001 SHR+LN compared to SHR, SHR+E,
and SHR+E+LN).
4. Discussion
This study utilized the SHR to look into the relationship
between oxidative stress, kidney damage, and blood pressure
lowering effect of enalapril in hypertension in a time-course
manner, as this model has been shown to be excellent for the
study of hypertension [33]. The SHR+L-NAME model was
incorporated into the study so as to hasten the kidney damage
and thereby shorten the study period. Zhou and Frohlich
[23] showed the suitability of this model whereby they started
the L-NAME inhibition on 17-week-old SHR, producing clear
nephropathy in 3 weeks. Similarly, in our study, L-NAME
inhibition was commenced at around the same age, that is,
at 16 weeks, and continued for 12 weeks until 28 weeks so as
to ensure that significant and extensive nephropathy occurs,
which was confirmed by our histopathology, proteinuria,
and creatinine clearance results. L-NAME inhibition was not
started at an earlier age as enhancing hypertension rapidly at
a younger agemight affect the survival rate of the rats. Overall
the study time points of 4 weeks, 16 weeks, and 28 weeks were
selected so as to observe the changes from prehypertension
to established hypertension and finally hypertensive kidney
damage periods. The 16- and 28-week study time points
were also selected as our previous research showed that
this age period had greater increase in blood pressure and
antioxidant changes [34]. Enalapril, a widely used ACEi class
of antihypertensive drugs, was used for this study as it has
been said to have renoprotective properties but the exact
mechanism for this is not known [35]. The enalapril and L-
NAME doses used in this study are similar to what has been
used by other researchers [36, 37].
Results obtained showed that SBP of untreated SHR
was already elevated to hypertensive levels at 8 weeks of
age. This is in agreement with other researchers who noted
hypertension in SHR at around this age [38, 39].This elevated
blood pressure increased progressively with a sharp increase
occurring between the ages of 16 and 28 weeks. Chronic
inhibition of nitric oxide synthase with L-NAME to SHR,
initiated at 16 weeks, caused significant increase in SBP from
20 weeks onwards when compared to untreated SHR. SBP
exceeded more than 200mmHg after 4 weeks of adminis-
tration and reached more than 220mmHg at the end of the
experimental period at 28 weeks. This confirmed the effect
of L-NAME on SBP as obtained by other researchers [24–
26]. Enalapril administration to SHR succeeded in lowering
the SBP within normal limits. However, for the SHR+LN
group, enalapril administration did not effectively reduce the
SBP to normal whereby the values were about 155mmHg at
24 to 28 weeks (Figure 3). The blood pressure of enalapril
treated and untreated WKY rats was normal and relatively
unchanged throughout the study. However the WKY+LN
group showed elevated SBP, almost similar to the SHR+LN
group (data not shown).Here, again, enalapril administration
did not effectively reduce the SBP to normal. The reason for
both these situations could be because the enalapril dose used
was insufficient to overcome the inhibition effects caused by
L-NAME.
SHR showed significantly lower body weight than age-
matchedWKY from 10weeks onwards (data not shown).This
could be due to various factors including metabolic changes
associated with hypertension, stress, and poorer appetite.
The absolute kidney weight of untreated SHR, SHR+LN,
and SHR+E+LN at 28 weeks was significantly higher than
SHR+E. The kidney to body weight ratio was also increased
in a similar pattern (Figures 1 and 2). This is probably due
to hypertrophy of various structures in the kidney brought
about by hypertension which causes the kidney weight to
increase as well as the lower body weight of these groups
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which results in a reduced kidney to body weight ratio.
Similar findings were reported by researchers experimenting
on different animal models of hypertension [40, 41].
The histopathology results of this study confirmed the
effect of L-NAME in producing kidney damage as clear
pathological changes were seen in the glomerulus, tubules,
and blood vessels at 28 weeks (Figures 4(D)-4(E)). Besides
this, urine protein was markedly increased and the creatinine
clearance was greatly reduced. Enalapril treatment managed
to prevent this damage, confirming its renoprotective effect
through blood pressure lowering as mentioned by other
researchers [35].
Oxidative stress has been implicated in the pathogenesis
and progression of hypertension with some studies suggest-
ing it is the cause while others suggest it is a consequence of
hypertension [4, 5, 42, 43]. Results from this study showed
that TAS levels are significantly reduced at 28 weeks in
SHR+LN rats when compared to the other groups. Also,
TBARS levels are significantly raised in SHR and SHR+LN
rats during the same time period. These findings indicate the
presence of oxidative stress in the kidneys of these groups.
The SBP of these rat groups during this time period was also
very high, exceeding 200mmHg, indicating a strong rela-
tionship with oxidative stress. Enalapril treatment, besides
reducing the SBP, also managed to prevent this oxidative
stress by reducing the TBARS levels as well as enhancing
the TAS levels (Figures 5 and 6). SOD levels at 28 weeks
were significantly reduced in the SHR and SHR+LN rats.
These levelswere restored to earlier 4-week and 16-week levels
when enalapril was administered (Figure 7). CAT activity in
the SHR group was significantly raised at 16 weeks and 28
weeks when compared to the other groups. It is possible
that this overexpressed CAT activity during this time might
be a compensatory mechanism to protect the kidney from
the deleterious effects of free radicals involved in causing
oxidative stress. The CAT activity in the SHR+LN group
was significantly reduced at 28 weeks when compared to
the other groups. This could be due to some unknown
mechanism in the oxidative stress process that has affected its
activity. Enalapril treatment managed to normalise the CAT
activity to earlier levels (Figure 8). All these findings clearly
indicate that enalapril has antioxidative properties.This study
also supports the view that enalapril has renoprotective
properties which might be conferred through the reduction
or elimination of oxidative stress in the kidney as has been
shown for other antioxidants [44].
5. Conclusion
This study showed that enalapril, in addition to blood pres-
sure lowering properties, also has beneficial effect in reducing
oxidative stress in the kidneys.
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